May. 7 at 11:37 AM
$TNDM The analysts that are coming out ahead of earnings with ‘Strong Buy’ recommendation; I wonder how many endocrinologists they’ve spoken with to research their recommendation.
Endos are seriously scrambling to offload Tandem users onto other systems due to Trusteel inventory availability and lack of guidance for resolution.
Many long-term Tandem customers cannot switch to Teflon based cannulas due to reactions or scarring from years of use.
$MMED will be the primary beneficiary of the off-cycle pump and supply switching wave.
